Terry Heiman-Patterson, MD, Professor of Neurology at the Lewis Katz School of Medicine at Temple University, spoke with PhillyVoice about the results of the phase 2 trial for AMX0035, a treatment for amyotrophic lateral sclerosis (ALS) that combines two existing drugs, sodium phenylbutyrate and tauroursodeoxycholic acid, to target two different facets of the disease’s progression. Dr. Heiman-Patterson was the principal investigator at Temple.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH
Related News
Major Advances in Treating Lung Blood Clots Could Eliminate Need for ICU Stay, According to New Research at the Lewis Katz School of Medicine at Temple University
Posted November 22, 2024A novel “on-the-table” therapeutic strategy with a total procedure time of less than one hour can safely reduce the size of blood clots lodged in the pulmonary arteries and eliminate the need for post-procedural drug infusion in an intensive care unit, according to Katz School of Medicine research.
Read MoreHealio Highlights Dr. Kristin Criner’s Session at the GOLD International COPD Conference
Posted November 21, 2024Healio highlighted the key takeaways from Dr. Criner’s session on how to identify and treat patients with COPD plus diabetes or osteoporosis.
Read More